These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17166600)

  • 1. Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.
    Ji C; Brandt M; Dioszegi M; Jekle A; Schwoerer S; Challand S; Zhang J; Chen Y; Zautke L; Achhammer G; Baehner M; Kroetz S; Heilek-Snyder G; Schumacher R; Cammack N; Sankuratri S
    Antiviral Res; 2007 May; 74(2):125-37. PubMed ID: 17166600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies.
    Zhang J; Rao E; Dioszegi M; Kondru R; DeRosier A; Chan E; Schwoerer S; Cammack N; Brandt M; Sankuratri S; Ji C
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1386-97. PubMed ID: 17242138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor.
    Ji C; Zhang J; Dioszegi M; Chiu S; Rao E; Derosier A; Cammack N; Brandt M; Sankuratri S
    Mol Pharmacol; 2007 Jul; 72(1):18-28. PubMed ID: 17392523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency.
    Jekle A; Chow E; Kopetzki E; Ji C; Yan MJ; Nguyen R; Sankuratri S; Cammack N; Heilek G
    Antiviral Res; 2009 Sep; 83(3):257-66. PubMed ID: 19559732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
    Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
    AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
    Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies.
    Blanpain C; Vanderwinden JM; Cihak J; Wittamer V; Le Poul E; Issafras H; Stangassinger M; Vassart G; Marullo S; Schlndorff D; Parmentier M; Mack M
    Mol Biol Cell; 2002 Feb; 13(2):723-37. PubMed ID: 11854425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analyses of anti-HIV type 1 activity of a small CCR5 peptide antagonist.
    Wang FY; He SY; Zhang ZJ; He LF; Chen XW; Teng T
    AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1111-5. PubMed ID: 21375388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
    Imamura S; Ichikawa T; Nishikawa Y; Kanzaki N; Takashima K; Niwa S; Iizawa Y; Baba M; Sugihara Y
    J Med Chem; 2006 May; 49(9):2784-93. PubMed ID: 16640339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.
    Lalezari J; Yadavalli GK; Para M; Richmond G; Dejesus E; Brown SJ; Cai W; Chen C; Zhong J; Novello LA; Lederman MM; Subramanian GM
    J Infect Dis; 2008 Mar; 197(5):721-7. PubMed ID: 18266604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of acute and chronic cardiac allograft rejection in mice by inhibition of chemokine receptor 5 in combination with cyclosporine A.
    Li J; Xia J; Zhang K; Xu L
    J Surg Res; 2009 Nov; 157(1):81-90. PubMed ID: 19577762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES.
    Nardese V; Longhi R; Polo S; Sironi F; Arcelloni C; Paroni R; DeSantis C; Sarmientos P; Rizzi M; Bolognesi M; Pavone V; Lusso P
    Nat Struct Biol; 2001 Jul; 8(7):611-5. PubMed ID: 11427892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
    Seto M; Aikawa K; Miyamoto N; Aramaki Y; Kanzaki N; Takashima K; Kuze Y; Iizawa Y; Baba M; Shiraishi M
    J Med Chem; 2006 Mar; 49(6):2037-48. PubMed ID: 16539392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CCR5, a new target of anti-HIV drugs].
    Han YX; Jiang JD
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):635-9. PubMed ID: 14650176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly potent HIV inhibition: engineering a key anti-HIV structure from PSC-RANTES into MIP-1 beta/CCL4.
    Gaertner H; Lebeau O; Borlat I; Cerini F; Dufour B; Kuenzi G; Melotti A; Fish RJ; Offord R; Springael JY; Parmentier M; Hartley O
    Protein Eng Des Sel; 2008 Feb; 21(2):65-72. PubMed ID: 18178567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
    Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
    AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric effects of antagonists on signalling by the chemokine receptor CCR5.
    Haworth B; Lin H; Fidock M; Dorr P; Strange PG
    Biochem Pharmacol; 2007 Sep; 74(6):891-7. PubMed ID: 17669370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.